GlassScriptPhysician profile
Terry Ellen Parsons
NPI 1407342074
$6,047.22
in general payments reported to CMS, 2019-2025
33 companies · $897 in 2025
The $897 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $631 · 2021: $1,274 · 2022: $253 · 2023: $609 · 2024: $2,147 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,027 · Debt Forgiveness: $626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,026.60 |
| Debt Forgiveness | $626.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $897.45 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Photonicare INC | $626.26 | 2024 | Otosight Middle Ear Scope |
| Abbvie INC. | $616.99 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $497.99 | 2022-2025 | |
| Axsome Therapeutics, INC. | $457.23 | 2024-2025 | Auvelity |
| Glaxosmithkline, LLC. | $449.27 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $304.62 | 2020-2025 | Farxiga, Airsupra |
| Pfizer INC. | $294.05 | 2020-2025 | |
| Novo Nordisk INC | $288.22 | 2020-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $226.89 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $180.64 | 2020-2025 | Spravato |
| Stryker Corporation | $159.30 | 2024 | Inbone, Infinity Adaptis |
| Idorsia Pharmaceuticals US INC | $112.57 | 2023-2024 | Quviviq |
| Amarin Pharma, INC. | $112.07 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.64 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $92.72 | 2023-2024 | Rexulti |
| Astellas Pharma US INC | $85.97 | 2020-2021 | |
| Amgen INC. | $83.90 | 2021-2024 | Prolia, Evenity |
| Novartis Pharmaceuticals Corporation | $72.80 | 2019 | |
| Esperion Therapeutics, INC. | $70.70 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.79 | 2020-2021 | |
| Daiichi Sankyo INC. | $41.60 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $23.89 | 2021 | |
| Exact Sciences Corporation | $23.33 | 2024 | Cologuard Collection Kit |
| Allergan, INC. | $22.95 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.34 | 2022 | |
| Abiomed | $20.82 | 2024 | Impella |
| Hologic Sales and Service, LLC | $20.04 | 2019 | |
| Currax Pharmaceuticals LLC | $17.79 | 2021 | |
| Paratek Pharmaceuticals, INC. | $16.89 | 2024 | Nuzyra |
| Chiesi USA, INC. | $16.78 | 2019 | |
| Optinose US, INC. | $14.07 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Parsons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.